Aurobindo Pharma Ltd., incorporated in the year 1986, is a Large Cap company (having a market cap of Rs 57597.77 Crore) operating in Pharmaceuticals sector.
Financials
For the quarter ended 31-03-2021, the company reported a Consolidated Total Income of Rs 6079.60 Crore, down -6.44 % from last quarter Total Income of Rs 6498.31 Crore and down -1.80 % from last year same quarter Total Income of Rs 6191.02 Crore. Company reported net profit after tax of Rs 809.55 Crore in latest quarter.
Investment Rationale
The brokerage has reduced FY22E/FY23E EPS estimate by 3%/2% to reflect COVID related slowdown in Europe/growth markets and increased R&D spends towards complex products. It continues to value ARBP at 16x 12-months forward earnings to arrive at TP of INR1,150. It remains positive on the back of: a) ARBP building a diverse and robust complex portfolio over the next 2-4 years, b) enhanced product offerings as well as improving profitability in Europe, c) vaccine prospects, and d) lower financial leverage
Promoter/FII Holdings
Promoters held 51.9 per cent stake in the company as of March 31, 2021, while FIIs held 24.4 per cent, DIIs 13.2 per cent and public and others 10.5 per cent.
(Views and recommendations given in this section are the analysts’ own and do not represent those of ETMarkets.com. Please consult your financial adviser before taking any position in the stock/s mentioned.)
